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INTRODUCTION
Pancreatic cancer (PC) is 
one of the most aggressive types 
of human malignancies and a 
major health problem. Pancreatic 
cancer is a relatively rare type 
of tumor, but due to its high 
mortality rate it is one of the most 
frequent causes of cancer death 
in the world.[1] In developed 
countries the incidence of PC is 
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ABSTRACT
Background & Aims: Pancreatic cancer is a devastating disease with poor prognosis. There is very limited 
information available regarding the epidemiology and treatment strategies of pancreatic cancer in Central 
Europe. The purpose of the study was to prospectively collect and analyze data of pancreatic cancer in the 
Hungarian population.
Methods: The Hungarian Pancreatic Study Group (HPSG) organized prospective, uniform data collection. 
Altogether 354 patients were enrolled from 14 Hungarian centers. 
Results: Chronic pancreatitis was present in 3.7% of the cases, while 33.7% of the patients had diabetes. 
Family history for pancreatic cancer was positive in 4.8%. The most frequent presenting symptoms included 
pain (63.8%), weight loss (63%) and jaundice (52.5%). The reported frequency of smoking and alcohol 
consumption was lower than expected (28.5% and 27.4%, respectively). The majority of patients (75.6%) were 
diagnosed with advanced disease. Most patients (83.6%) had a primary tumor located in the pancreatic head. 
The histological diagnosis was ductal adenocarcinoma in 90.7% of the cases, while neuroendocrine tumor 
was present in 5.3%. Biliary stent implantation was performed in 166 patients, 59.2% of them received metal 
stents. Primary tumor resection was performed in 60 (16.9%) patients. Enteral or biliary bypass was done 
in 35 and 49 patients, respectively. In a multivariate Cox-regression model, smoking status and presence of 
gemcitabine-based chemotherapy were identified as independent predictors for overall survival.
Conclusion: We report the first data from a large cohort of Hungarian pancreatic cancer patients. We identified 
smoking status and chemotherapy as independent predictors in this cohort.
Key words: pancreatic cancer – Hungarian cohort – acute pancreatitis – chronic pancreatitis – diabetes mellitus.
Abbreviations: EBM: evidence-based medicine; EPI: exocrine pancreatic insufficiency; FNAB: fine needle 
aspiration biopsy; HPSG: Hungarian Pancreatic Study Group; MDCT: multi-detector computed tomography; 
OS: overall survival; PC: pancreatic cancer; RPP: Registry for Pancreatic Patients
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the seventh, and the mortality rate is the fifth among all cancers 
[2]. In Hungary both the incidence and mortality are one of 
the highest in Europe. There were 2,373 newly diagnosed PC 
patients in Hungary in 2010, and 1,837 died due to the disease 
[3]. 
The number of patients with PC is increasing globally. It 
is estimated that in 2012 there were 103,773 newly diagnosed 
cases and 104,463 fatal outcomes in Europe [4]. There are 
no screening tests for early detection of PC. By the time of 
diagnosis, less than 15% of patients can be offered a potential 
curative treatment, and up to 30% of the patients die within 
12 months [5]. 
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Data suggest that the onco-epidemiological situation 
related to pancreatic cancer in Central European countries 
is even worse compared to that in the Western world [6]. An 
epidemiologic analysis from 51 countries across the world has 
shown the highest mortality rates in Central Europe with trends 
towards increasing mortality in Romania, along with Albania, 
Spain and Croatia [7]. An epidemiologic study conducted in 
Serbia between 1991 and 2010 demonstrated high mortality 
rates with increasing mortality trend in both genders and in 
most age groups [8]. 
There is only limited information available on the 
management of PC from Central Europe including Hungary. 
In order to improve outcome of PC, it is essential to determine 
which factors contribute to the unfavorable trends seen in less 
developed countries. The main purpose of our study was to 
collect information regarding the diagnosis, management and 
outcome of pancreatic cancer in Hungary. Here we present 
the first large prospectively collected and analyzed data of 
pancreatic cancer in the Hungarian population.  
PATIENTS AND METHODS
The Hungarian Pancreatic Study Group (HPSG) was 
established in 2011 in order to improve the care of patients 
suffering from pancreatic diseases. To achieve our aims we 
(i) developed an electronic data registry for patients (www.
pancreas.hu), (ii) published the currently available evidence-
based medicine (EBM) guidelines [9-13], (iii) established 
specific study sessions including the pancreatic cancer one, 
(iv) and organized multicenter clinical trials [14-17].
For this study the HPSG collected data from patients 
diagnosed with PC between September 2012 and March 
2014 using uniform questionnaire and clinical data sheets. 
Patients were enrolled from 14 Hungarian centers including 
endoscopy units, gastroenterological, oncological and surgical 
departments. The characteristics of the single departments and 
the number of patients enrolled by each center are summarized 
in Table I. 
Demographic data, data of possible risk factors, symptoms, 
diagnosis, staging, therapy and survival were assessed. Data 
collection was performed using a web-based electronic data 
collection method as part of the Registry for Pancreatic Patients 
(RPP).
Demographic data included age and gender of patients. 
Information about alcohol consumption and smoking 
(frequency and total amount of daily consumption), body mass 
index (BMI), history of acute and chronic pancreatitis, diabetes 
mellitus and familial PC has been collected as possible risk 
factors. Frequency of symptoms and clinical signs, such as fever, 
pain, diarrhea, jaundice and weight loss were also evaluated.  
Cancer related data included the date of diagnosis, extension 
of the disease, location of the primary tumor, histological type, 
the method used to obtain histological diagnosis and the level 
of CA 19-9 at the time of diagnosis. Diagnosis and staging 
of pancreatic cancer was based on imaging tests including 
multi-detector computed tomography (MDCT), magnetic 
resonance imaging (MRI), endoscopic retrograde cholangio-
pancreatography (ERCP) and endoscopic ultrasonography 
(EUS). Primary resectable tumor, locally advanced and 
metastatic disease were distinguished. Histological diagnosis 
was performed using brush cytology during ERCP, fine needle 
aspiration biopsy (FNAB) or surgical biopsy/resection.
The database included information on endoscopic, surgical, 
oncological and supportive therapy performed. The proportion 
of plastic or metal stents used for biliary drainage was 
determined. Information on the frequency of duodenal stent 
implantation was also recorded. Data on surgical resection 
(including margin status; R0, R1, R2) has been collected for 
patients with a resectable primary tumor. Palliative biliary 
and enteral bypass were recorded as well. If a patient received 
oncological treatment (radiation therapy or chemotherapy) 
for PC, the type and intent (neo-adjuvant, adjuvant, palliative) 
of therapy and the name of the chemotherapeutic agent used 
Table I. Characteristics of the participating centers
Name of institution Type of institution Department profile Number of patients 
enrolled (n)
Borsod-Abaúj-Zemplén County General Hospital, Miskolc General Hospital Gastroenterology 2
Bács-Kiskun County Municipality Hospital, Kecskemét General Hospital Gastroenterology 2
Pándy Kálmán Békés County Hospital, Gyula General Hospital Gastroenterology 11
Department of Interventional Gastroenterology, National 
Institute of Oncology, Budapest
National Institution Endoscopy Unit 27
Institute of Surgery, Clinical Center, University of Debrecen University Hospital Surgery 18
Department of Surgery, University of Pécs University Hospital Surgery 41
First Department of  Medicine, University of Pécs, Hungary University Hospital Gastroenterology 29
First Department of Internal Medicine, University of Szeged University Hospital Gastroenterology 89
Second Department of Internal Medicine, University of Szeged University Hospital Gastroenterology 7
Department of Oncotherapy, University of Szeged University Hospital Oncology 18
Department of Surgery, University of Szeged University Hospital Surgery 55
First Department of Medicine, Szent György University Teaching 
Hospital of County Fejér, Székesfehérvár
General Hospital Gastroenterology 43
First Department of Surgery, Semmelweis University, Budapest University Hospital Surgery 2
Dr. Réthy Pál Hospital, Békéscsaba General Hospital Gastroenterology 10
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were also noted. Data collected on supportive therapy consisted 
of pancreatic enzyme replacement, pain control and the 
management of diabetes mellitus. 
Information on survival status was obtained from the 
Hungarian Central Statistical Office. Survival was defined as 
the number of months between date of diagnosis and date of 
death (if known). 
The research involved human participants. All data have 
been collected after the patients had given written informed 
consent. The study was approved by the Secretary of Medical 
Research Council, Scientific and Research Ethics Committee, 
approval number 22254-1/2012/EKU (391/PI/2012).
Statistical analysis
Statistical analysis with one-way ANOVA and Student 
t-test was performed. Survival data was analysed by plotting 
Kaplan-Meier curves and LogRank test. A multivariate Cox-
regression analysis was performed to identify independent 
predictors of overall survival. Variables with a p value of <0.2 
were included in the Cox-regression analysis, in addition 
gender and location of the tumor were added as arbitrary 
variables. Values are expressed as means ± standard deviation 
(SD) if not stated otherwise. A P value <0.05 was considered 
statistically significant.
RESULTS
Three hundred fifty-four patients were enrolled into the 
study. Mean age of the population was 65.2 years (SD 11.5, 
range: 23-88 years). There were more males than females 
(53.4% vs. 46.6%, respectively). 
Risk factors
One hundred and one patients (28.5%) were recorded as 
smoking regularly. Twenty-eight patients (7.9%) were smoking 
more than 20 cigarettes per day. Alcohol consumption was 
reported in 97 patients (27.4%), whereas 44 (12.4%) were 
drinking alcohol on a daily basis. Data on BMI at the time of 
diagnosis was available for 297 patients (83.9%). The time of 
diagnosis was defined as the date of the first imaging modality 
(CT scan, MRI or ERCP) performed giving the diagnosis of 
pancreatic cancer. One hundred and seventy-one (57.6%) 
patients had a normal BMI (normal range: 18.5-24.99 kg/m2), 
while 103 (34.6%) were overweight (BMI: 25.0-29.99 kg/m2) 
and 23 (7.7%) were obese (BMI ≥ 30.0 kg/m2). 
Only 8 patients (2.3%) had a positive history for recurrent 
acute pancreatitis, 13 (3.7%) were diagnosed with chronic 
pancreatitis. Approximately one third of the population 
(n=119, 33.7%) had diabetes; almost half (n=57, 47.9%) of 
them were using insulin. Positive family history for pancreatic 
cancer was found in 13 patients (3.6%). 
Symptoms and signs
The most frequent symptoms at the time of diagnosis were 
abdominal pain and weight loss (unexplained loss of more 
than 5% of the body weight within six month), which were 
present in 63.8% and 63% of all patients. Jaundice (bilirubin 
concentration higher than 35 µmol/L) was found in 52.5%. 
Interestingly, there was only a small difference in the frequency 
of jaundice between patients having a tumor in the pancreatic 
head (53.1%) and those having the cancer in the body or tail 
(50%). Diarrhea was recorded in 13.8% of the patients, 7.9% 
had fever. Newly diagnosed diabetes was found in 2.3% of the 
studied population. The cancer was recognized accidentally in 
6.5%; these patients were symptom free. Presenting symptoms 
are summarized in Fig. 1.  
Fig. 1. Incidence of symptoms and clinical signs at the time of 
diagnosis. 
Cancer related data
Information on tumor stage was missing in 29 cases 
(8.2%). Seventy-nine patients (24.3%) had resectable disease. 
The tumor was located to the pancreatic head in the majority 
(77.2%) of resectable cases (n=61), while 7 (8.9%) patients had 
cancer located in the body and 11 (13.9%) in the tail of the 
pancreas.The proportion of locally unresectable and metastatic 
cancer at initial diagnosis is shown in Table II. 
Table II.  Distribution of pancreatic cancer cases by disease stage.
Disease stage Number of patients (n) Percentage (%)
Resectable 79 24.3
Locally advanced 138 42.4
Metastatic 108 33.2
In the majority of cases (n=285, 80.5%) the primary tumor 
was located in the head of the pancreas. Cancer of the body and 
tail was found in 27 and 29 cases (7.6% and 8.2%, respectively). 
Tumor location was unknown in 13 cases (3.7%). 
Histological/cytological diagnosis was available for 227 
patients (64.1%). The diagnosis was obtained via image guided 
fine needle aspiration biopsy (59.7%), brush cytology during 
ERCP (11.6%), or surgical biopsy/resection (28.7%). The 
biopsy revealed ductal adenocarcinoma in the majority of the 
cases (n=206, 90.7%). Adenocarcinoma of the papilla of Vater 
was confirmed in 5 cases (2.2%), while 12 patients (5.3%) had 
neuroendocrine carcinoma. There were 2 cases of intraductal 
papillary-mucinous carcinoma, one case of solid-pseudo-
papillary carcinoma and one unique case of histologically 
proven diffuse large B-cell lymphoma located in the pancreas.
Serum CA 19-9 level was investigated for ductal 
adenocarcinoma and Vater’s papilla carcinoma (n=211) at the 
time of initial diagnosis. Data were available for 83 patients. 
The level of CA 19-9 was elevated in 65 cases (78%).
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Therapy
Biliary stent implantation during ERCP was performed in 
166 cases. Metal stents were used more commonly than plastic 
ones (59% vs. 40.1%, respectively). Duodenal stent placement 
for small bowel obstruction was reported in only two cases. 
From the 79 patients with a resectable primary tumor, 
60 underwent surgical resection. The distribution of tumor 
location of surgical cases was consistent with data reported 
on resectable cases: head 50 (83.3%), body 4 (6.7%), tail 6 
(10%). Fifty patients had tumor free resection margins (R0), 
four patients had microscopic (R1) and six macroscopic (R2) 
residual disease.  There is no information available why 19 
patients with resectable pancreatic tumor did not undergo 
surgery. Palliative surgical treatment was performed in 84 cases. 
Thirty-five patients underwent enteral bypass, while biliary 
bypass reconstruction was performed in 49 cases (Table III). 
Table III. Surgical treatment






Unresectable (n=246) Palliative 84
Enteral bypass 35
Biliary bypass 49
There is very limited data available in terms of the 
oncological treatment used in the studied population. Most 
information on oncotherapy originated from oncology 
departments presenting their cases. Only one patient was 
reported to have received radiotherapy with palliative intent for 
neuroendocrine carcinoma. Administration of chemotherapy 
was recorded in 42 cases. Nine patients received adjuvant 
treatment; palliative therapy was used in 33 cases. Every 
patient received gemcitabine-based chemotherapy. Neither 
the FOLFIRINOX regimen, nor nab-paclitaxel was used in 
this cohort of patients. There is no reported case in which 
neo-adjuvant chemotherapy was given. 
Information about the use of analgesics was available in 
179 patients (50.6%). Regular intake of painkillers was found 
in 73 cases (40.8%). Minor analgesics were needed for 56 
patients (31.3%), while 43 patients (24%) were administered 
major analgesics for severe pain. It should be noted that 58.9% 
(43/73) of the patients suffering from pain would have needed 
major analgesics. 
Exocrine pancreatic insufficiency (EPI) affects the 
majority of patients with pancreatic cancer. Pancreatic enzyme 
replacement therapy is recommended to relieve EPI-related 
gastrointestinal symptoms. Data on enzyme replacement 
therapy is available for 311 patients. Supportive treatment of 
the studied population is summarized in Table IV. 
Survival
Survival data is available for 194 patients. Survival was 
defined as the number of months between the date of diagnosis 
and date of death. Overall survival (OS) for the whole 
population was 8.7 months. 
Table IV. Supportive treatment (some patients received both minor and 
major analgesics).
Type of therapy 
(number of data available)
Number of patients (n) Percentage (%)






Overall survival of patients with histologically proven 
ductal adenocarcinoma (n=133) was 9.97±1.77 months. 
Neuroendocrine carcinoma patients had a better prognosis 
with an OS of 14±5.21 months. However, survival data is 
available for only 4 patients with a neuroendocrine tumor. 
There is no information available regarding the survival of 
patients with carcinoma of the papilla of Vater.
Overall survival of ductal adenocarcinoma patients 
was significantly different according to smoking habits 
(pLogRank=0.049, Fig. 2A) and for patients who have 
received gemcitabine based chemotherapy (p=0.013, Fig. 2B) 
in a Kaplan-Meier analysis  The number of curative surgical 
resections was low (n=19), survival data were not available 
from 10 patients and OS was not analysed according to the 
surgical resection status. There was no association between 
gender, tumor stage, location, alcohol consumption, diabetes, 
presence of lymph node metastasis or BMI and OS. In a 
multivariate Cox-regression model, smoking status and 
presence of gemcitabine-based chemotherapy were identified 
as independent predictors for overall survival (Table V).
Table V. Overall survival of patients with pancreatic ductal adenocarcinoma 
according to gender, smoking status, alcohol consumption, location and 
chemotherapy.
P-value Hazard Ratio 95% CI
Gender 0.84
Alcohol consumption 0.15
Smoking 0.016        




No data 0.016 2.08 1.15–3.77
No 0.027 1.75 1.07-2.88
Yes Reference
DISCUSSION
Recently, PC has shown an increasing trend in incidence 
rates among both men and women [18]. The number of cases 
of PC in Central Europe is also increasing, mortality rates in 
this region are among the highest in the world [7]. 
There is very limited data available about the management 
and outcome of PC in Hungary. In order to improve the prognosis 
of PC, it is essential to determine which factors contribute to the 
high mortality rates seen in Central Europe. 
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We report the first data from a large cohort of Hungarian 
PC patients. Patients were enrolled from departments with 
different profiles. Most of the data was provided by university 
centres or general hospitals with a teaching function. The 
proportion of patients enrolled by the smaller hospitals was 
low, which is a limitation of the study. Data were compared to 
results from published literature.
There are multiple risk factors possibly related to PC. 
Smoking counts as the strongest environmental risk factor for 
PC. A meta-analysis reported an elevated risk of PC both for 
current and former smokers [19]. In the Hungarian cohort 
28.5% of patients were smoking regularly, which reflects the 
smoking habits in Hungary (28.9% of the adult population 
were smoking in 2012 in Hungary) [20]. The rate of current 
smokers among patients with PC was the same as the average 
current smoker rate in the general population. These data do 
not support the relationship between smoking and the elevated 
risk of PC. Alcohol consumption contributes to episodes of 
acute pancreatitis, and is the most common cause of chronic 
pancreatitis. It seems reasonable that heavy alcohol consumption 
elevates the risk of PC. In our cohort regular consumption of 
alcohol was reported in 27.4% of the patients. 
Chronic pancreatitis has been proposed as an independent 
risk factor for PC and explains about 3% of the cases [21]. In 
our study, the prevalence of both acute recurrent and chronic 
pancreatitis was low. The rate of chronic pancreatitis was 
consistent with literature data. There were 13 patients with 
positive family history of PC; the youngest patient was 23 years 
old. Over the past decades multiple studies have reported a 
positive association between diabetes and PC [22].  However, 
as diabetes could be a manifestation of PC, the link between 
diabetes and the risk of cancer is controversial. New onset 
diabetes probably should be evaluated in a different manner 
than the diabetes lasting for more than 3 years. Hyperglycemia 
or manifest diabetes is present in 50-80% of patients diagnosed 
with PC. In our cohort, approximately one third of the patients 
had diabetes and half of them were using insulin at the time 
of diagnosis. There is no information about the duration of 
diabetes before the diagnosis of PC. Obesity and overweight 
have been shown to be risk factors for PC [22]. Most of the 
patients in our study had a normal BMI or were overweight. 
Prevalence of the presenting symptoms was consistent with 
literature data. The most frequent symptoms at the time of 
diagnosis were abdominal pain and weight loss. The location of 
the tumor did not affect the prevalence of jaundice, which was 
present in more than half of the patients. New onset diabetes 
was found in only 2.3% of the studied population. 
Histological diagnosis was not available in more than one 
third of the patients. In most cases histology was performed via 
image guided fine needle aspiration biopsy. In accordance with 
literature data [24], histology revealed ductal adenocarcinoma 
in the majority of the cases. Twelve patients had neuroendocrine 
carcinoma, while other subtypes were only found occasionally. 
In this study neuroendocrine carcinoma patients had a better 
prognosis than patients with ductal adenocarcinoma.  Overall 
survival for the whole population was 8.7 months. The location 
of the tumor was predominantly in the head of the pancreas. 
Serum CA 19-9 level was found to be elevated in 78% of the 
cases with ductal adenocarcinoma and carcinoma of the papilla 
of Vater. The rate of false-negativity was 22%, which confirms 
that CA 19-9 determination cannot be used as a screening test 
for the detection of pancreatic cancer [25]. 
About 15 to 20 percent of patients with PC have resectable 
disease at the time of diagnosis [26]. In this cohort more 
patients had resectable or locally advanced tumors (24.3% and 
42.4%, respectively) as recorded in the literature. One third of 
the patients had metastatic disease at initial diagnosis. From the 
79 patients with a resectable primary tumor, 60 had underwent 
surgical resection, most of them having R0 resection. Median 
survival following surgical resection ranges between 11.2 and 
25.5 month [27]. Since OS data were available for only a few 
patients (n=9) who had undergone surgical resection, survival 
data were not analysed according to the surgical resection 
status. Information is lacking why 19 patients with resectable 
pancreatic tumor did not undergo surgery. Inappropriate 
overall status or comorbidities may have been the cause that 
these patients were not eligible for surgery. 
Fig. 2. Overall survival of patients with pancreatic ductal 
adenocarcinoma according to smoking status (A) and 
chemotherapy (B).
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Biliary obstruction (defined as extrahepatic obstruction 
of the common bile duct causing jaundice [bilirubin>35 
µmol/L]) was seen in 52.5% of the patients. It is controversial 
whether metal or plastic stents should be used for biliary 
obstruction caused by PC. In a recent study the use of metal 
stents was associated with an outcome benefit [28]. In our 
cohort metal stents were used more frequently than plastic 
ones. Gastrointestinal obstruction was resolved via palliative 
enteral bypass surgery in most of the cases. Endoscopic stent 
placement was performed in only two cases, which can be 
explained by the fact that self-expandable enteral stents are not 
financially reimbursed, therefore not available at the majority 
of Hungarian endoscopy units. 
Information about oncological therapy was only available 
from oncology department patients. There was no recorded 
administration of radiotherapy for patients with ductal 
adenocarcinoma, which reflects that radiotherapy is not used in 
routine clinical practice for PC in Hungary. Gemcitabine-based 
chemotherapy was administered in all cases. Although, the 
FOLFIRINOX regimen has shown significant survival benefit 
for selected patients in PC [29], there are only some centers 
in Hungary using this protocol; it is not used routinely. The 
nab-paclitaxel plus gemcitabine regimen has recently become 
a first-line treatment option for patients with metastatic PC 
[30]. Nab-paclitaxel is currently not available in Hungary. There 
was no association between gender, tumor stage, location, 
alcohol consumption, diabetes, presence of lymph node 
metastasis or BMI and overall survival. Smoking status and 
presence of gemcitabine-based chemotherapy were identified 
as independent predictors for overall survival.
Information on supportive therapy is missing in many 
cases. It should be emphasized that the majority of patients 
suffering from pain would be in need of the use of major 
analgesics. Exocrine pancreatic insufficiency (EPI) affects the 
majority of patients with pancreatic cancer. Pancreatic enzyme 
replacement therapy is recommended to alleviate EPI-related 
gastrointestinal symptoms and improve quality of life. In our 
cohort only 16.7% of the patients received pancreatic enzyme 
substitution.
CONCLUSIONS
In the Hungarian cohort, the frequency of both acute 
recurrent and chronic pancreatitis was low. Most patients 
had histologically proven ductal adenocarcinoma; the other 
histological subtypes were rare. Biliary stent placement is a 
routine intervention for the management of biliary obstruction 
occurring in PC. Hungarian endoscopists use more metal stents 
than plastic ones. In cases of enteral obstruction, palliative 
surgical bypass is the preferred approach compared with the 
endoscopic placement of duodenal stents. Smoking status and 
presence of gemcitabine-based chemotherapy were identified 
as independent predictors for overall survival. Future plans 
of the HPSG include improving the quality of data collection 
and the extension of the database to other Central and Eastern 
European countries. 
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